Ryu Kyung Kim

Ryu Kyung Kim

Auto-generated profile, based on publicly available information

Ryu Kyung Kim

Korea Disease Control and Prevention Agency, Cheongju, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JLJu Hee Lee
Ju Hee Lee
JHJi Hae Hwang
Ji Hae Hwang
EJEun Jung Jang
Eun Jung Jang
RKRyu Kyung Kim
Ryu Kyung Kim
KLKil Hun Lee
Kil Hun Lee
YPYoung-Joon Park
Young-Joon Park
Lee JH, et al. J Korean Med Sci. 2023 Aug;38(34):e269. https://doi.org/10.3346/jkms.2023.38.e269

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YKYoo-Yeon Kim
Yoo-Yeon Kim
YCYoung June Choe
Young June Choe
JKJia Kim
Jia Kim
RKRyu Kyung Kim
Ryu Kyung Kim
EJEun Jung Jang
Eun Jung Jang
YPYoung-Joon Park
Young-Joon Park
Kim YY, et al. J Korean Med Sci. 2023 Mar;38(11):e87. https://doi.org/10.3346/jkms.2023.38.e87

10 August 2023 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CCChungman Chae
Chungman Chae
RKRyu Kyung Kim
Ryu Kyung Kim
EJEun Jung Jang
Eun Jung Jang
JSJi Ae Shim
Ji Ae Shim
EPEunkyung Park
Eunkyung Park
DKDonghyok Kwon
Donghyok Kwon
To compare the effectiveness of bivalent and monovalent COVID-19 vaccines throughout the 2022-2023 winter season based on real-world data. This retrospective observational matched cohort study used the national vaccination program and a surveillance dataset from the Republic of Korea, and included adults aged >18 years who received bivalent or monovalent COVID-19 vaccines between October 11, 2022, and December 17, 2022. Cox proportional hazard models were used to estimate the hazard ratio for COVID-19 infection between the groups. We included 29,245 matched individuals in the bivalent and monovalent vaccine groups, respectively. The bivalent vaccine recipients showed 12.2% (95% confidence interval [CI] 6.5-17.7%) additional protection against COVID-19 infection compared with the monovalent vaccine recipients. The additional protection provided by bivalent vaccines was significantly higher among residents of long-term care facilities (39.4%, 95% CI 21.6-53.1%). Maximum additional protection was observed 3 to 4 months after completing the vaccination (17.6%, 95% CI 6.6-27.3%). Bivalent COVID-19 vaccines showed significantly better protection against infection than monovalent vaccines among adults during the 2022-2023 winter season. Our results highlight that immunization programs with bivalent vaccines comprising recent variants can be an effective measure to prepare for seasonal COVID-19 circulation.

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
RKRyu Kyung Kim
Ryu Kyung Kim
YCYoung June Choe
Young June Choe
EJEun Jung Jang
Eun Jung Jang
CCChungman Chae
Chungman Chae
JHJi Hae Hwang
Ji Hae Hwang
DKDonghyok Kwon
Donghyok Kwon
Kim RK, et al. J Korean Med Sci. 2023 Nov;38:e396. https://doi.org/10.3346/jkms.2023.38.e396

14 October 2022 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
EJEun Jung Jang
Eun Jung Jang
YCYoung June Choe
Young June Choe
SCSeung-Ah Choe
Seung-Ah Choe
YKYoo-Yeon Kim
Yoo-Yeon Kim
RKRyu Kyung Kim
Ryu Kyung Kim
YPYoung-Joon Park
Young-Joon Park
Objectives: We estimated the overall and age-specific percentages of the Korean population with presumed immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as of April 2022 using the national registry. Methods: We used the national coronavirus disease 2019 (COVID-19) infection and vaccination registry from South Korea, as described to define individuals with a previous history of COVID-19 infection, vaccination, or both, as persons with presumed immunity.Results: Of a total of 53,304,627 observed persons, 24.4% had vaccination and infection, 58.1% had vaccination and no infection, 7.6% had infection and vaccination, and 9.9% had no immunity,. The SARS-CoV-2 Omicron variant emerged at a time when the presumed population immunity ranged from 80% to 85%; however, nearly half of the children were presumed to have no immunity.Conclusion: We report a gap in population immunity, with lower presumed protection in children than in adults. The approach presented in this work can provide valuable informed tools to assist vaccine policy-making at a national level.

1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
SPSeon Kyeong Park
Seon Kyeong Park
YCYoung June Choe
Young June Choe
EJEun Jung Jang
Eun Jung Jang
RKRyu Kyung Kim
Ryu Kyung Kim
SLSang-Won Lee
Sang-Won Lee
YPYoung-Joon Park
Young-Joon Park
Park SK, et al. J Korean Med Sci. 2023 Apr;38(19):e143. https://doi.org/10.3346/jkms.2023.38.e143